Ratings for Viridian Therapeutics (NASDAQ:VRDN) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Insights from analysts’ 12-month price targets are revealed, presenting an average target of $29.5, a high estimate of $42.00, and a low estimate of $23.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 6.05%. Understanding Anal…